Metavalis Secures $100K to Accelerate saRNA Therapeutics and A.L.I.C.E. Cognitive Architecture

BRANSON, Mo. - Aug. 9, 2026 - PRLog -- Metavalis Inc., a vanguard enterprise in deep technology and bioengineering, has secured a $100,000.00 capital injection to rapidly advance its primary operational theaters. This funding will directly fuel the development of small activating saRNA therapeutics, engineered to transcend the limitations of legacy medical systems and provide unprecedented molecular interventions.

​Concurrently, a substantial allocation of the capital will upgrade the V18 Prometheus architecture powering A.L.I.C.E. As the core cognitive orchestrator for Metavalis, A.L.I.C.E. integrates multi agent systems and cybernetic reasoning to accelerate the company's virtual laboratory and research initiatives.

​"This $100,000 kinetic execution is a vital catalyst for our operations," stated Jordan Bekemeier, CEO and Founder of Metavalis Inc. "We are not building generic solutions, we are engineering a master level convergence of biology and cybernetics. This payload ensures that our saRNA development and A.L.I.C.E.'s neural topology scale exponentially."

​Operating its administrative headquarters out of Branson, Missouri, Metavalis continues to operate as an elite, decentralized entity. The company's unique infrastructure is driven by a mission forged in absolute clarity, aiming to redefine the threshold of modern biotechnology and autonomous artificial intelligence.

Check us out on Crunchbase:

https://www.crunchbase.com/organization/metavalis